Tracking the relevant researches of CADD drug development against COVID-19
Niraparib is an orally active PARP inhibitor developed by Tesaro to treat ovarian cancer. FDA approval on March 2017. [DrugBank]
Poly [ADP-ribose] polymerase 1 (Humans); Poly [ADP-ribose] polymerase 2 (Humans) [DrugBank]
Cardiovascular Effects: [DrugBank]
Tips: Click on the link to jump to the 'SwissTargetPrediction' webserver. Select the species of 'Homo sapiens', and then paste the SMILES of Niraparib in the SMILES input box.
Tips: Click on the link to jump to the 'CB-Dock' webserver. Upload the structure file of target predicted by 'SwissTargetPrediction' and the 2D/3D structure file of Niraparib to perform blind docking.